Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript

Nov 14, 2023 / 03:55PM GMT
Release Date Price: $49.15 (+4.49%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

All right. Very good. It's my pleasure to be hosting this panel with Brett Monia, CEO of Ionis. I'm sure most folks know the Ionis story quite well. But maybe I can just have Brett give a quick 2- to 3-minute intro the scope of the pipeline, what's kind of key and that's upcoming, and then we can get into Q&A. So thank you.

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

It sounds good. Pleasure to be here, Paul. Thank you. So Ionis is a genetic medicines company traditionally has been focused on the antisense platform. Today, we're more diversified in our technology. Certainly, [antisense is a key to our] technology with 9 drugs in Phase III development for 11 indications.

But we've also expanded our capabilities into RNAi and even gene editing now. It's been a very exciting year for the pipeline with several positive readouts and preparing for upcoming commercial launches next year

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot